Index60 Is Superior to HbA1c for Identifying Individuals at High Risk for Type 1 Diabetes.


Journal

The Journal of clinical endocrinology and metabolism
ISSN: 1945-7197
Titre abrégé: J Clin Endocrinol Metab
Pays: United States
ID NLM: 0375362

Informations de publication

Date de publication:
28 09 2022
Historique:
received: 11 11 2021
pubmed: 27 7 2022
medline: 30 9 2022
entrez: 26 7 2022
Statut: ppublish

Résumé

HbA1c from ≥ 5.7% to < 6.5% (39-46 mmol/mol) indicates prediabetes according to American Diabetes Association guidelines, yet its identification of prediabetes specific for type 1 diabetes has not been assessed. A composite glucose and C-peptide measure, Index60, identifies individuals at high risk for type 1 diabetes. We compared Index60 and HbA1c thresholds as markers for type 1 diabetes risk. TrialNet Pathway to Prevention study participants with ≥ 2 autoantibodies (GADA, IAA, IA-2A, or ZnT8A) who had oral glucose tolerance tests and HbA1c measurements underwent 1) predictive time-dependent modeling of type 1 diabetes risk (n = 2776); and 2) baseline comparisons between high-risk mutually exclusive groups: Index60 ≥ 2.04 (n = 268) vs HbA1c ≥ 5.7% (n = 268). The Index60 ≥ 2.04 threshold was commensurate in ordinal ranking with the standard prediabetes threshold of HbA1c ≥ 5.7%. In mutually exclusive groups, individuals exceeding Index60 ≥ 2.04 had a higher cumulative incidence of type 1 diabetes than those exceeding HbA1c ≥ 5.7% (P < 0.0001). Appreciably more individuals with Index60 ≥ 2.04 were at stage 2, and among those at stage 2, the cumulative incidence was higher for those with Index60 ≥ 2.04 (P = 0.02). Those with Index60 ≥ 2.04 were younger, with lower BMI, greater autoantibody number, and lower C-peptide than those with HbA1c ≥ 5.7% (P < 0.0001 for all comparisons). Individuals with Index60 ≥ 2.04 are at greater risk for type 1 diabetes with features more characteristic of the disorder than those with HbA1c ≥ 5.7%. Index60 ≥ 2.04 is superior to the standard HbA1c ≥ 5.7% threshold for identifying prediabetes in autoantibody-positive individuals. These findings appear to justify using Index60 ≥ 2.04 as a prediabetes criterion in this population.

Identifiants

pubmed: 35880956
pii: 6650147
doi: 10.1210/clinem/dgac440
pmc: PMC9516117
doi:

Substances chimiques

Autoantibodies 0
Blood Glucose 0
C-Peptide 0
Glycated Hemoglobin A 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2784-2792

Subventions

Organisme : NIDDK NIH HHS
ID : U01 DK107014
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK085476
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK085466
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK106993
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK103282
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK061058
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK107013
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK061034
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK103180
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK061042
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK106984
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK085453
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK085499
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK061010
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK085465
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK106994
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK103153
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK085504
Pays : United States
Organisme : NIDDK NIH HHS
ID : UC4 DK106993
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK103266
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK085461
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK085509
Pays : United States

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Références

Diabetes Care. 2022 Feb 1;45(2):311-318
pubmed: 34853027
Diabetes Care. 2012 Jun;35(6):1213-8
pubmed: 22446173
J Clin Endocrinol Metab. 2010 Jul;95(7):3360-7
pubmed: 20444913
Diabetologia. 2021 Apr;64(4):836-844
pubmed: 33496819
Diabetes Care. 2017 Nov;40(11):1494-1499
pubmed: 28860125
Pediatr Diabetes. 2009 Apr;10(2):97-104
pubmed: 18823409
Diabetes Care. 2018 Jan;41(Suppl 1):S13-S27
pubmed: 29222373
Diabetologia. 2020 Mar;63(3):588-596
pubmed: 31768570
Diabetes Care. 2015 Oct;38(10):1964-74
pubmed: 26404926
Pediatr Diabetes. 2016 Jul;17 Suppl 22:25-30
pubmed: 27411433
JCI Insight. 2018 Aug 9;3(15):
pubmed: 30089716
Diabetes Care. 2010 Mar;33(3):620-5
pubmed: 20032282
Pediatr Diabetes. 2019 May;20(3):263-270
pubmed: 30628751
Diabetes Care. 2012 Sep;35(9):1821-5
pubmed: 22699293
Diabetes Care. 2015 Feb;38(2):271-6
pubmed: 25519451

Auteurs

Laura M Jacobsen (LM)

Division of Pediatric Endocrinology, University of Florida, Gainesville, FL 32610, USA.

Brian N Bundy (BN)

Health Informatics Institute, University of South Florida, Tampa, FL 33620, USA.

Heba M Ismail (HM)

Department of Pediatrics, Indiana University, Indianapolis, IN 46202, USA.

Mark Clements (M)

Pediatric Endocrinology, Children's Mercy, Kansas City, MO 64111, USA.

Megan Warnock (M)

Health Informatics Institute, University of South Florida, Tampa, FL 33620, USA.

Susan Geyer (S)

Health Informatics Institute, University of South Florida, Tampa, FL 33620, USA.

Desmond A Schatz (DA)

Division of Pediatric Endocrinology, University of Florida, Gainesville, FL 32610, USA.

Jay M Sosenko (JM)

Division of Endocrinology, University of Miami, Miami, FL 33136, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH